Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 3/20 | 0.43 |
| ▸ | FLT3 | P36888 | 5/20 | 0.42 |
| ▸ | RAF1 | P04049 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718597 | 0.98 | BRAF (0.46) | BRAFMEN1NPC1RAB9AKMT2A | |
| SCHEMBL4717784 | 0.95 | BRAF (0.46) | BRAFMEN1NPC1RAB9AKMT2A | |
| SCHEMBL4719821 | 0.92 | BRAF (0.46) | BRAFMEN1NPC1RAB9AKMT2A | |
| SCHEMBL4718146 | 0.90 | MEN1 (0.48) | BRAFMEN1NPC1RAB9AKMT2A | |
| SCHEMBL4719574 | 0.89 | MEN1 (0.48) | BRAFMEN1NPC1RAB9AKMT2A | |
| SCHEMBL4718598 | 0.89 | BRAF (0.45) | BRAFMEN1NPC1RAB9AKMT2A | |
| SCHEMBL4717345 | 0.87 | MEN1 (0.49) | BRAFMEN1NPC1RAB9AKMT2A | |
| SCHEMBL4719244 | 0.87 | BRAF (0.49) | BRAFRETRAF1 | |
| SCHEMBL4719736 | 0.86 | BRAF (0.51) | BRAFRETRAF1 | |
| SCHEMBL4721107 | 0.86 | BRAF (0.51) | BRAFFLT3RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737462-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | claimed |
| EP-1737462-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20080027076-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| EP-1737462-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005060969-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027076-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | BRAF 2020/4885MEN1 1106/4885NPC1 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.